Quantcast

Latest Polypill Stories

2010-10-03 19:05:00

Diabetes control and cardiovascular risks sustained over 4 years An intensive lifestyle intervention program designed to achieve and maintain weight loss improves diabetes control and cardiovascular disease risk factors in overweight and obese individuals with type 2 diabetes, according to four-year results of the Look AHEAD study, funded by the National Institutes of Health and the Centers for Disease Control and Prevention. The results are published in the Sept. 27, 2010, issue of the...

2010-06-01 19:49:16

Experts are now recommending that low-dose aspirin therapy to prevent heart attacks be used somewhat more conservatively "“ that men younger than 50 and women younger than 60, who have diabetes but no other major risk factors, probably not use aspirin. The new recommendations are based on an analysis of nine studies, which found that the risks of some side effects such as stomach bleeding, and to a much less extent bleeding strokes, have to be better balanced against the potential...

2009-11-03 06:57:44

Researchers at the University of Warwick have identified a particular combination of health problems that can double the risk of heart attack and cause a three-fold increase in the risk of mortality. The team, led by Assistant Clinical Professor of Public Health at Warwick Medical School Dr Oscar Franco, has discovered that simultaneously having obesity, high blood pressure and high blood sugar are the most dangerous combination of health factors when developing metabolic syndrome. Metabolic...

2009-10-08 15:53:00

WILMINGTON, N.C., Oct. 8 /PRNewswire/ -- CardioPharma is beginning the final funding phase before submitting an NDA for CardiaPill, the world's first patented triple-combination cardiovascular polypill. "The recent news from Kaiser Permanente reinforces that in this cost containment and efficacy oriented healthcare environment, CardiaPill is in the right place at the right time," stated Don Sellers, CardioPharma's Chairman and CEO. "After our recent meeting with the FDA we believe the...

2009-09-21 08:12:11

Many people are not receiving the best possible care when it comes to managing cardiovascular conditions according to two new Australian research studies. The studies highlight the need for wide scale reform to ensure that people at the highest risk of having a heart attack or stroke are identified early and are provided with optimal care. The studies give a comprehensive snapshot of the state of cardiovascular care in the primary health care system for both Indigenous and non-Indigenous...

2009-04-02 09:33:21

 A five-in-one pill that may cut a person's risk of cardiovascular disease by 50 to 60 percent was well-tolerated by participants in the first study to evaluate the pill in humans.Polycap, or the "polypill," is a combination of three blood pressure lowering drugs, a statin and aspirin.Researchers examined the impact of the polypill and eight other drug therapies on cardiovascular health measures like blood cholesterol and heart rate in 2,053 participants in India. Throughout the 12-week,...

9e01871681ed11adf65a6960e9b0a8e21
2009-03-30 13:30:00

A major study has found promising new results for an experimental pill that could serve as a one-size-fits-most treatment to prevent heart attacks and stroke. The so-called "polypill" is made up of aspirin, three blood pressure-lowering drugs and a cholesterol-lowering statin drug. Researchers noted that the polypill proved to be equally as effective as each of its components are when taken alone. Additionally, they found that the polypill could effectively cut a person's risk of heart...

2009-02-25 23:21:52

Lowering blood pressure protects dialysis patients from major cardiovascular events and death, researchers in Australia said. The study, published in The Lancet, also said that treatment with blood-pressure lowering drugs should be routinely considered for patients undergoing dialysis. Vlado Perkovic of The George Institute for International Health in Australia said people who receive dialysis for chronic kidney disease are at high risk of cardiovascular events and death -- every year about...

2008-12-17 14:44:27

The U.S. Food and Drug Administration is recommending companies developing type 2 diabetes drugs and biologics evaluate the products' cardiovascular risks. The FDA said pharmaceutical companies should provide evidence the therapy will not increase the risk of such cardiovascular events as a heart attack. The recommendation applies to all diabetes drugs currently under development. We need to better understand the safety of new anti-diabetic drugs. Therefore, companies should conduct a more...

2008-11-13 18:00:24

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor(R) system, which measures central blood pressures and arterial stiffness noninvasively, today announced that a new study* funded by the National Institutes of Health (NIH) found that when patients' central pulse pressures exceeded 50 mm of mercury, there was a significant increase in cardiovascular events. The 2,405 patient study was presented on November 12 at the 2008 American Heart Association Scientific Sessions in...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.